INSTIL BIO
Instil Bio is a cell therapy company developing tumor infiltrating lymphocytes for the treatment of solid tumor cancers. It is advancing its proprietary manufacturing expertise, technology, and data into clinical trials, including a planned registrational study with its candidate and the first-in-human study of its next-generation engineered TIL.
INSTIL BIO
Industry:
Biotechnology Health Care Life Science Medical
Founded:
2018-01-01
Address:
Dallas, Texas, United States
Country:
United States
Website Url:
http://www.instilbio.com
Total Employee:
101+
Status:
Active
Total Funding:
200.2 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Google Tag Manager WordPress Google Universal Analytics Font Awesome Domain Not Resolving Global Site Tag
Similar Organizations
Innovative BioTherapies
Innovative BioTherapies is a biotechnology company that develops medical devices to solve unmet medical needs.
Seismic Therapeutic
Seismic Therapeutic is a biotechnology company advancing machine learning for immunology drug development.
Current Employees Featured
Bronson Crouch Chairman & CEO @ Instil Bio
Chairman & CEO
Vijay Chiruvolu Chief Technical Officer @ Instil Bio
Chief Technical Officer
Zachary Roberts Chief Medical Officer @ Instil Bio
Chief Medical Officer
Sandeep Laumas Chief Financial Officer @ Instil Bio
Chief Financial Officer
Robert Hawkins Chief Strategy Advisor / Founder @ Instil Bio
Chief Strategy Advisor / Founder
2020-07-01
Amanda Longden Senior Human Resources Manager @ Instil Bio
Senior Human Resources Manager
2021-07-01
Tom Ramos Senior Scientist @ Instil Bio
Senior Scientist
2021-10-01
Founder
Stock Details
Investors List
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series C - Instil Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2022-09-09 | Dallas-based Instil Bio hires biotech veteran as new COO |
Official Site Inspections
http://www.instilbio.com Semrush global rank: 2.67 M Semrush visits lastest month: 6.26 K
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Instil Bio"
Instil Bio - LinkedIn
Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. Instil seeks to in-license/acquire and develop novel therapeutic candidates in ...See details»
Instil Bio - Crunchbase Company Profile & Funding
Instil Bio is a cell therapy company developing tumor infiltrating lymphocytes for the treatment of solid tumor cancers. It is advancing its proprietary manufacturing expertise, technology, and …See details»
Instil Bio 2025 Company Profile: Stock Performance & Earnings
Instil Bio General Information Description. Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating …See details»
Instil Bio - Craft
Oct 29, 2024 Instil Bio (formerly Immetacyte, Cellular Therapeutics) is an immuno-oncology company that specializes in cell therapies. Its technology platform is based on the use of …See details»
Instil Bio, Inc. Company Profile | Dallas, TX - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Instil Bio, Inc. of Dallas, TX. Get the latest business insights from Dun & Bradstreet.See details»
Instil Bio - Overview, News & Similar companies | ZoomInfo.com
Instil Bio contact info: Phone number: (972) 499-3350 Website: www.instilbio.com What does Instil Bio do? Instil Bio is a clinical-stage biopharmaceutical company focused on developing a …See details»
FAQs - Instil Bio
• You can reach Instil Bio Investor Relations by email at investor.relations@instilbio.com. How can I get added to Instil Bio’s mailing list? • You can sign up for e-mail alerts notifying you of new …See details»
Working At Instil Bio: Company Overview and Culture - Zippia
Mar 14, 2024 instilbio.com. Organization Type. Public. CEO. Bronson Crouch. Social Media. Instil Bio is a biotechnology company that develops cell therapies for solid tumor cures. The …See details»
Instil Bio Company Profile -Sales, Contacts, Competitors – Buzzfile
Instil Bio, Inc. (trade name Instil Bio) is in the Biological Products, except Diagnostic business. View competitors, revenue, employees, website and phone number.See details»
Home - Instil Bio
© 2025 Instil Bio. All Rights Reserved Privacy Policy Terms of Service Agency Policy Terms of Agreement. To the top ↑ Up ↑ ↑ Up ↑See details»
Instil Bio Announces Strategic Update - Yahoo Finance
DALLAS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor …See details»
Instil Bio Announces Strategic Update - GlobeNewswire
Jan 16, 2024 www.instilbio.com. Recommended Reading. May 13, 2025 07:00 ET | Source: Instil Bio. Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate …See details»
Presentations | Instil Bio
Mar 4, 2025 The Investor Relations website contains information about Instil Bio's business for stockholders, potential investors, and financial analysts.See details»
Instil Bio takes the ax to its lead asset, cutting 60% of its staff in ...
Dec 8, 2022 Instil Bio is calling it quits on its lead tumor-infiltrating lymphocyte therapy and four corresponding programs, a major overhaul of the company’s priorities that’s resulting in 60% …See details»
News Release - Instil Bio
For more information visit www.instilbio.com and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities …See details»
Contact Us - Instil Bio
Send us a message.See details»
Instil Bio Overview | SignalHire Company Profile
Instil Bio is a cell therapy company developing tumor infiltrating lymphocytes for the treatment of solid tumor cancers. It is advancing its proprietary manufacturing expertise, technology, and …See details»
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in
9 hours ago The updated clinical safety from the full ‘2510 monotherapy trial (n=106) and efficacy data in NSCLC are further detailed in a new corporate deck posted on Instil Bio’s …See details»
Instil Bio and ImmuneOnco Announce Phase 2 Trial Update for
9 hours ago Potential Positives. The initiation of a Phase 3 trial for ‘2510 in combination with chemotherapy for first-line NSCLC in China highlights the company's commitment to …See details»
Pipeline - Instil Bio
Target Candidate Indication Discovery Pre-clinical Phase 1 Phase 2 Phase 3 Rights; PD-L1xVEGF : AXN-2510 (Publications) Multiple Solid TumorsSee details»